Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1995-06-07
1997-09-23
Weddington, Kayln E.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
514256, A61K 3133, A61K 31505
Patent
active
056704968
ABSTRACT:
A method of reducing the severity of toxoplasmosis resulting from infection of a patient with Toxoplasma gondii by administering to a patient in need of such treatment, either after infection or before exposure to infection, a therapeutically effective amount of a compound that is a spiropiperidyl derivative of rifamycin S, wherein the derivative comprises an imidazole ring that includes carbons at positions 3 and 4 of the rifamycin ring, the carbon at position 2 of the imidazole ring also being a ring carbon at position 4 of a piperidine ring system, thereby forming a spiropiperidyl ring system, the spiropiperidyl ring system optionally comprising a lower hydrocarbon substituent on the nitrogen of the piperidine.
REFERENCES:
patent: 4086225 (1978-04-01), Marsili et al.
patent: 4219478 (1980-08-01), Marsili et al.
patent: 4327096 (1982-04-01), Marsili et al.
patent: 4738958 (1988-04-01), Franco et al.
patent: 4963531 (1990-10-01), Remington
Windholz et al., The Merck Index, p. 1152, abstract no. 7884 (1983).
Remington, J.S. and Desmonts, G. : In Infectious Diseases of the Fetus and Newborn Infant, 3rd Ed., J.S. Remington, J.O. Klein, eeds Philadelphia: WB Saunders Company (1990) pp. 89-195.
Remington, J.S. et al. "The effect of Rifampin Toxoplasma gondii" (1970) Proc. Soc. Ex. Biot. and Med: 135: 167-172.
Singleton, P. and Sainsbury, D. eds. (1987) Dictionary of Microbiology and Molecular Biology, 2nd Ed., John Wiley & Sons, Ltd., Bath (England) p. 769.
Physicians Desk Reference (1993) : pp. 1394-1397.
Woodley, C.L. and Kilburn, J.O. (1982) Am. Rev. Respir. Dis. 126:586-587.
Hoy, J. et al. (1990) J. Infect. Dis. 161: 801-805.
Araujo, F.G. et al. (1993) J. Infect. Dis. 167:494-7.
Ruskin, J. and Remington, J.S. (1976) Ann. Intern. Med. 84:193-199.
O'Brien, R.J. et al. (1987) Review of Infectious Diseases 9:519-529.
Araujo, F.G. (1992) Depletion of CD4+ T Cells But Not Inhibition of the Protective Activity of IFN-y J. Immunol. 149:3003-3007.
Araujo, F.G. et al. (1991) In Vivo Activity of the Macrolide Eur. J. Clin. Microbiol. Infect. Dis. 10:519-524.
Araujo, F.G. et al. (1992) In Vitro and In Vitro Activities of the Hydroxynaphthoquinone 566C80 Against the Cyst Form of Toxoplasma gondii. Antimicrob. Agents Chemother. 36:326-330.
Araujo, F.G. et al. (1991) Remarkable In vitro and In Vitro Activities of the Hydroxynaphthoquinone 566C80 Against Tachyzoites and Cysts of Toxoplasma Gondii. Antimicrob. Agents and Chemother. 35:293-299.
Araujo, F.G. et al. (1992) Clarithromycin--minocycline Is Synergistic in a Murine Model of Toxoplasmosis. J. Infect. Dis. 165:788.
Chiodini, R.J. et al. (1993) Use of rifabutin in Treatment of Systemic Mycobacterium Paratuberculosis Infection in Mice. Antimicrob. Agents Chemother. 37:1645-1648.
Dannemann, B. et al. (1992) Treatment of Toxoplasmic Encephalitis in Patients With Acquired Immunodeficiency Syndrome. Ann. Intern. Med. 116:33-43.
Dannemann, B. et al. (1988) Treatment of toxoplasmic Encephalitis with Intravenous Clidamycin. Arch. Intern. Med. 148:2477-2482.
Falloon, Judith, Current Therapy for HIV Infection and its Infectious Complications, (1992) Post Graduate Medicine, vol. 91, No. 8, pp. 115-132.
Ellner, J.J. et al. (1991) Mycobacterium Avium Infection in Aids. J. Infect. Dis. 163:1326-1335.
Heifets, L.B. et al. Bacteriostatic and Bactericidal Effects of Rifabutin Ansamycin, LM 427) on Mycobacterium Avium Clinical Isolates, pp. 180-183. In M. Casal (ed.) Mycobacteria of Clinical Interest (1986). Amesterdam: Elsevier Science.
Horsburgh, C.R. (1991). Myobacterium Avium Complex Infections in the Acquired Immunodeficiency Syndrome. N. Engl. J. Med. 324:1332-1338.
Hughes, W.T. et al. (1991) Safety an Pharmacokinetics of 566C80, a Hydroxynaphtopquinone with Anti-Pneumocystis Carinii Activity. J. Infect. Dis. 163:843-848.
Israelski, D.M. et al. Toxoplasmosis in Patients with AIDS, pp. 241-264 In The Medical Management of AIDS -(1990). M.A. Sande and P.A. Volberding (eds.) Philadelphia: W.B. Sounders.
Israelski, D.M. et al. (1989) Treatment with Anti-L3T4 (CD4) Monoclonal Antibody Reduces the Inflammatory Response in Toxoplasmic Encephalitis. J. Immunol. 142;954-958.
Narang, P.K. et al. (1992) Rifabutin Absorption in Humans; Relative Bioavailability and Food Effect. Clin. Pharmac. Therap. 52:335-341.
McCabe, R.E. et al. Toxoplasma gondii, pp. 2090-2103. In Third ed. Principles and Practice of Infectious Diseases -1990. G.L. Mandell et al. (eds.) London: Churchill Livingstone, Inc.
Hunter, C.A. et al. (1993) Cytokine mRNA in the Central Nervous System of SCID Mice Infected With Toxoplasma Gondii. Infect. Immun. 61:4038-4044.
Araujo Fausto G.
Remington Jack S.
Palo Alto Medical Foundation
Weddington Kayln E.
LandOfFree
Treatment for toxoplasmosis with a composition comprising a fola does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment for toxoplasmosis with a composition comprising a fola, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment for toxoplasmosis with a composition comprising a fola will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1938709